I don't think one would speak of the NIH as a "par

Quote:

---

I don't think one would speak of the NIH as a "partner"; it would be more like a "funder."

---

The positive of NIH funding is that we could get a trial done, get approval , get cash, do more trials and see a much greater appreciation in share price than any buyout offer from Merck. Any partnership from big pharma would certainly be contingent on a buyout especially with leronlimab being far superior to Keytruda.